Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin J Epstein

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
American Family Physician|December 26, 2006
Newer agents for the management of overactive bladderBenjamin J Epstein, John G Gums, Emerson Molina
Drugs|June 6, 2007
Dihydropyridine calcium channel antagonists in the management of hypertensionBenjamin J Epstein, Katherine Vogel, Biff F Palmer
Expert Review of Cardiovascular Therapy|November 11, 2009
Recent changes in the landscape of combination RAS blockadeBenjamin J Epstein, Steven M Smith, Rushab Choksi
Journal of the American Academy of Nurse Practitioners|January 9, 2009
The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBsCharon A Pierson, Benjamin J Epstein, Mary Ellen Roberts
Expert Review of Cardiovascular Therapy|August 17, 2012
The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyondBenjamin J Epstein, Paul T Leonard, Niren K Shah
Therapeutic Advances in Cardiovascular Disease|August 16, 2013
Management of hypertension with fixed-dose triple-combination treatmentsBenjamin J Epstein, Niren K Shah, Nancy L Borja-Hart
Pharmacotherapy|March 7, 2012
Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitusNiren K Shah, Wasim E Deeb, Rushab Choksi, et al.
The Annals of Pharmacotherapy|February 4, 2010
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonistShawn D Anderson, Niren K Shah, Juwon Yim, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 19, 2013
SGLT-2 inhibitors and their potential in the treatment of diabetesRebecca F Rosenwasser, Senan Sultan, David Sutton, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 7, 2011
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study)Niren K Shah, Steven M Smith, Wilmer W Nichols, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
American Family Physician|December 26, 2006
Newer agents for the management of overactive bladderBenjamin J Epstein, John G Gums, Emerson Molina
Drugs|June 6, 2007
Dihydropyridine calcium channel antagonists in the management of hypertensionBenjamin J Epstein, Katherine Vogel, Biff F Palmer
Expert Review of Cardiovascular Therapy|November 11, 2009
Recent changes in the landscape of combination RAS blockadeBenjamin J Epstein, Steven M Smith, Rushab Choksi
Journal of the American Academy of Nurse Practitioners|January 9, 2009
The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBsCharon A Pierson, Benjamin J Epstein, Mary Ellen Roberts
Expert Review of Cardiovascular Therapy|August 17, 2012
The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyondBenjamin J Epstein, Paul T Leonard, Niren K Shah
Therapeutic Advances in Cardiovascular Disease|August 16, 2013
Management of hypertension with fixed-dose triple-combination treatmentsBenjamin J Epstein, Niren K Shah, Nancy L Borja-Hart
Pharmacotherapy|March 7, 2012
Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitusNiren K Shah, Wasim E Deeb, Rushab Choksi, et al.
The Annals of Pharmacotherapy|February 4, 2010
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonistShawn D Anderson, Niren K Shah, Juwon Yim, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 19, 2013
SGLT-2 inhibitors and their potential in the treatment of diabetesRebecca F Rosenwasser, Senan Sultan, David Sutton, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 7, 2011
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study)Niren K Shah, Steven M Smith, Wilmer W Nichols, et al.
Pageof 3